We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

REZI:NYSEResideo Technologies, Inc. Analysis

Data as of 2026-05-22 - not real-time

$29.01

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Resideo Technologies (REZI) is trading at $29.01, well below its 20‑day, 50‑day and 200‑day SMAs (≈$36), placing it in a bearish technical environment. The RSI of 30.4 hints at oversold conditions, while a bearish MACD (line –2.70 vs signal –1.51) and a widening histogram support short‑term downside pressure, though volume is increasing and the price sits above the computed support of $26.72. The stock’s beta of >2 and a 30‑day volatility of ~72% underscore heightened market sensitivity.
Fundamentally, REZI posted 8% YoY revenue growth to $7.6 B with a 28.8% gross margin, but a negative profit margin (‑6.5%) and negative operating cash flow highlight profitability challenges. The company carries $3.5 B of debt (Debt/Equity >120%) against $440 M of cash, yet generates positive EBITDA ($858 M) and modest free cash flow ($128 M). Forward earnings are projected at $3.13 with a forward P/E of 9.3, well below the industry average of 29.5, and analysts rate the stock a “strong buy” with a $49 target, implying ~69% upside. The market’s “Extreme Greed” sentiment (Fear‑Greed Index 91.5) further fuels optimism despite the risks.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near technical support and oversold RSI
  • Increasing volume suggesting potential bounce
  • High upside potential relative to current price

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward EPS positivity and low forward P/E vs industry
  • Revenue growth and strong EBITDA
  • Analyst target price of $49 indicating ~69% upside

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Elevated debt load and negative operating cash flow
  • Potential value creation from ADI Global Distribution spin‑off
  • Sustained market optimism but high volatility and beta

Key Metrics & Analysis

Financial Health

Revenue Growth8.00%
Profit Margin-6.50%
P/E Ratio9.3
ROE-15.79%
ROA5.06%
Debt/Equity120.33
P/B Ratio1.8
Op. Cash Flow$-1216999936
Free Cash Flow$127.8M
Industry P/E29.5

Technical Analysis

TrendBearish
RSI30.4
Support$26.72
Resistance$41.76
MA 20$36.02
MA 50$36.09
MA 200$36.31
MACDBearish
VolumeIncreasing
Fear & Greed Index91.5

Valuation

Target Price$49.00
Upside/Downside68.91%
GradeUndervalued
TypeBlend

Risk Assessment

Beta2.27
Volatility71.96%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.